Cypress Capital’s Evogene EVGN Stock Holding History

Cypress Capital’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-40	Closed	-$260	–	170
2024 Q2	$260	Buy	+40	New	+$279	﹤0.01%	368

Other funds holding EVGN

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

RIG

Renaissance Investment Group Lenox, Massachusetts $508M AUM 30.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Cypress Capital's EVGN Position: Q3 2024 in Review

Cypress Capital sold out of Evogene (EVGN) in Q3 2024, closing a stake of 40 shares — an estimated $260 sold.

Cypress Capital first reported a position in EVGN in Q2 2024 and held it in 1 quarter. The position peaked at $260 in Q2 2024. 14 funds tracked by Wall St. Rank hold EVGN as of Q3 2024.

Cypress Capital reported no remaining Evogene position as of Q3 2024 after selling out during the quarter.
Cypress Capital sold 40 Evogene shares in Q3 2024, an estimated $260.
Cypress Capital first reported a position in Evogene in Q2 2024 and held it in 1 quarter.
Cypress Capital's Evogene position peaked at $260 in Q2 2024.
14 funds tracked by Wall St. Rank held Evogene as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.